Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s

WTI crude jumped roughly 5% to $106 per barrel amid Middle East uncertainty, while the 10-year Treasury yield reached its highest level since 2007 as oil-driven inflation concerns intensified ahead of the Fed decision. Markets expected a 25bp rate hike and focused on the updated Fed dot plot for the policy-rate outlook. Wells Fargo's Q3 net interest margin was tracking roughly flat to 1bp below its 2.43% Q2 level, modestly better than guidance for a 3-4bp decline, while Eli Lilly was upgraded by Berenberg amid roughly $60B committed to more than 25 business-development deals in 2026.

Analysis

The rates/oil combination is unfavorable for long-duration equities and deposit-sensitive banks, but WFC’s modest NIM resilience matters because consensus has likely embedded another sequential deterioration. The stock can rerate over the next 1-3 months if deposit beta remains contained while loan yields reset higher; however, a further bear-steepening is not unambiguously bullish if it drives higher funding costs, credit losses, or mortgage/origination weakness. WFC is the cleaner expression than BCS, whose earnings remain more exposed to UK/European rate paths and investment-banking cyclicality.

LLY’s acquisition program should be valued as capital-allocation optionality rather than near-term earnings accretion. Its premium multiple leaves little tolerance for clinical or launch execution misses, but successful diversification reduces the market’s eventual concern that obesity revenues face pricing pressure, capacity constraints, or GLP-1 competition. The Sept. 30 combination-data event is a near-term catalyst; positive tolerability and incremental efficacy would reinforce duration value, whereas merely incremental data could trigger a crowded-position de-risking despite no change to the core franchise.

ATAI is no longer simply a psychedelic-therapy beta if the transaction closes on expected terms: it becomes a source of milestone and integration execution risk for LLY rather than an independent valuation compounder. The non-obvious second-order beneficiary is the neuropsychiatry biotech complex, where strategic scarcity may compress risk-adjusted discount rates, but only for assets with differentiated late-stage data—not early platform stories. Higher real yields can overwhelm this effect in the near term.

Consensus may overread a single quarter of WFC NIM and underprice the macro asymmetry: sustained energy-led inflation would force a more restrictive terminal-rate narrative, compressing both bank credit quality and LLY’s multiple. The key distinction is whether yields rise on real growth or inflation risk; the latter is negative for both positions.

Key Decisions for Investors

• Initiate a tactical long WFC / short BCS pair for 1-3 months. Use a 8-10% stop on relative performance; thesis is WFC NIM stabilization and domestic rate leverage versus BCS’s more mixed geographic and capital-markets exposure. Exit if WFC reports renewed NIM compression beyond roughly 4 bps sequentially or materially raises deposit-cost guidance.
• Maintain LLY core exposure but do not chase ahead of Sept. 30 data; add only on a 7-10% event-driven pullback if combination data supports differentiated tolerability or weight-loss efficacy. Size for a 15-20% drawdown risk given premium valuation; trim if data are non-differentiated or management signals that deal spending is diluting EPS/FCF beyond prior expectations.
• Use XLE versus IWM as a 1-2 month macro hedge against persistent energy-driven inflation: long XLE/short IWM benefits if higher fuel costs and real yields pressure smaller companies’ financing costs. Reduce if crude retreats below $95/bbl or the Fed signals a clearly imminent easing path.
• Do not initiate ATAI on strategic-takeover optics alone. Monitor deal completion, contingent-value-right terms, and any competing-bid process; absent those details, standalone downside from transaction uncertainty and biotech duration sensitivity outweighs the limited remaining upside.